<DOC>
	<DOCNO>NCT01198873</DOCNO>
	<brief_summary>Primary Objective : - Evaluate effect dronedarone versus placebo ( standard therapy ) slow progression adverse leave atrial remodel patient atrial fibrillation ( AF ) follow 12 month treatment . Secondary Objectives : - Evaluate effect dronedarone versus placebo leave atrial function ; - Evaluate effect dronedarone versus placebo leave atrial dimension ; - Evaluate effect dronedarone versus placebo leave ventricular function ( LVEF , E , E ' , A , E/E ' ) - Evaluate safety tolerability dronedarone .</brief_summary>
	<brief_title>Effects Dronedarone Cardiac Geometry Function Patients With Atrial Fibrillation Left Atrial Enlargement</brief_title>
	<detailed_description>The plan total study period per participant 12 month 3 week broken follow : - Screening period : 1 week ; - Treatment period : 12 month ; - Follow-up period : 2 week .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Amiodarone</mesh_term>
	<criteria>Inclusion criterion : Signed write informed consent Health Insurance Portability Accountability Act ( HIPAA ) Authorization ; Nonpermanent AF AF/Atrial Flutter ( AFL ) document electrocardiographically AF ( AF/AFL ) sinus rhythm within prior 12 month ; At screening , sinus rhythm Left Atrial Volume index ( LAVi ) ≥32 mL/m2 base 2Dechocardiography ; At least one follow cardiovascular ( CV ) risk factor : Age &gt; 70 year start screening , hypertension , diabetes mellitus , prior CV accident ( stroke transient ischemic attack ) systemic embolism , leave ventricular ejection fraction &lt; 0.40 . Exclusion criterion : Permanent AF define continuous AF 6 month longer ; Persistent AF define sustain AF &gt; 7 day duration and/or require cardioversion 4 week screening ; Prior valvular heart surgery significant valvular heart disease include rheumatic heart disease acquire valvular heart disease ; Aortic mitral regurgitation great mild ( &gt; 1+ ) degree mitral stenosis screen echocardiogram ; Myocardial infarction within 6 month prior screen stroke within 2 month prior screen ; Pacemaker , implantable cardioverter defibrillator , cardiac resynchronization therapy device place within 6 month prior screen anytime study ; Ongoing potentially dangerous symptom AF/AFL angina pectoris , transient ischemic attack , stroke , syncope judge Investigator ; Cardiac ablative procedure cardiac surgery within 3 month prior screen , percutaneous coronary intervention within 4 week prior screen ; Need concomitant medication prohibit trial , would preclude use study drug plan study period include follow : Antiarrhythmics ( eg , amiodarone , flecainide , propafenone , quinidine , disopyramide , dofetilide , sotalol ) ; Drugs product strong inhibitor CYP3A ( eg , ketoconazole , itraconazole , voriconazole , cyclosporine , telithromycin , clarithromycin , nefazodone , ritonavir , grapefruit juice ) ; Drugs inducer CYP3A ( eg , rifampin , phenobarbital , carbamazepine , phenytoin , St John 's wort ) ; QTc Bazett interval ≥500 msec screen ECG ; Bradycardia &lt; 50 bpm and/or PR interval ≥0.28 sec screen ECG unless patient functional pacemaker ; New York Heart Association ( NYHA ) Class IV heart failure NYHA Class II III heart failure recent decompensation require hospitalization referral specialized heart failure clinic within 4 week prior screen . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>